PDS Biotechnology Corp (PDSB) - Dilution Analysis

10-Q filing | 55.5M shares outstanding

8-K filing: PDS Biotechnology Corporation entered into a Securities Purchase Agreement with YA II PN, LTD. for a promissory note and a warrant to purchase common stock, with transactions expected to close around June 12, 2026.

10-K filing | 55.8M shares outstanding

10-Q filing | 46.9M shares outstanding

8-K filing: PDS Biotechnology Corporation entered into a securities purchase agreement for the sale and issuance of shares of common stock, pre-funded warrants, and common warrants, with an expected closing on November 12, 2025. ($5.28M proceeds)

S-3 filing: PDS Biotechnology Corporation is filing an S-3 form to register the offering and selling, from time to time, in one or more offerings, shares of common stock, shares of preferred stock, debt securities, warrants or units that include any of these securities, or rights to purchase shares of common stock, shares of preferred stock, debt securities or units, with an aggregate initial offering price of up to $200,000,000.

10-Q filing | 45.9M shares outstanding

S-3 filing: This prospectus relates to the resale, from time to time, of up to 9,818,340 shares of our common stock by the selling stockholders identified in this prospectus.

10-Q filing | 45.7M shares outstanding

8-K filing: PDS Biotechnology Corporation entered into a Securities Purchase Agreement to sell Senior Secured Convertible Debentures and warrants for a total purchase price of $20,000,000 and the transactions were consummated on April 30, 2025.

10-K filing | 45.4M shares outstanding

8-K filing: PDS Biotechnology Corporation entered into a securities purchase agreement for the sale and issuance of common stock, pre-funded warrants, and common warrants, resulting in expected gross proceeds of approximately $11 million, intended for research and development expenses, and general corporate purposes.

10-Q filing | 36.8M shares outstanding

10-Q filing | 36.7M shares outstanding

10-Q filing | 34.8M shares outstanding

10-K filing | 36.7M shares outstanding

10-Q filing | 30.9M shares outstanding

10-Q filing | 30.8M shares outstanding

10-Q filing | 30.4M shares outstanding

10-K filing | 28.6M shares outstanding

8-K filing: PDS Biotechnology Corporation entered into a License Agreement with Merck KGaA, Darmstadt, Germany, and issued 378,787 shares of its common stock to Merck KGaA in a private placement for $5.0 million. ($5.0M proceeds)

10-Q filing | 28.5M shares outstanding

8-K filing: PDS Biotechnology Corporation entered into a Venture Loan and Security Agreement and issued warrants to Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP to purchase an aggregate of 381,625 shares of common stock at an exercise price of $3.6685 per share, and also entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. and BTIG, LLC to offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million.

S-3 filing: PDS Biotechnology Corporation may offer and sell shares of common stock, shares of preferred stock, debt securities, warrants or units that include any of these securities, or rights to purchase shares of common stock, shares of preferred stock, debt securities or units, with an aggregate initial offering price of up to $150,000,000.

10-Q filing | 28.5M shares outstanding

10-Q filing | 26.2M shares outstanding

10-K filing | 28.4M shares outstanding

10-Q filing | 28.4M shares outstanding

10-Q filing | 28.4M shares outstanding

10-Q filing | 22.3M shares outstanding

10-K filing | 22.3M shares outstanding

10-Q filing | 5.3M shares outstanding

8-K filing: PDS Biotechnology Corporation completed an offering of 6,900,000 shares of common stock at $2.75 per share, resulting in gross proceeds of approximately $19.0 million. ($19.0M proceeds)

10-Q filing | 5.2M shares outstanding

S-3 filing: PDS Biotechnology Corporation is filing an S-3 to offer and sell shares of common stock, preferred stock, debt securities, warrants, units, or rights to purchase these securities, with an aggregate initial offering price of up to $100,000,000.

10-Q filing | 15.4M shares outstanding

10-K filing | 15.3M shares outstanding

8-K filing: PDS Biotechnology Corporation completed an offering of 9,230,770 shares of common stock at $1.30 per share, with certain members of management and NetScientific plc purchasing shares in the offering, resulting in approximately $11 million in net proceeds. ($11.0M proceeds)

S-1/A filing: PDS Biotechnology Corporation files an S-1/A registration statement for the sale of up to $13,800,000 of common stock.

S-1/A filing: This is an S-1/A filing for a common stock offering underwritten by A.G.P./Alliance Global Partners, including firm securities and an over-allotment option.